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1. Introduction 
The Inca alkaloid, vinblastine is often used as a 
tool to demonstrate the importance of lnicrotubul~s 
in celfular events because it binds with high affinity 
to specific sites on tubulin causing the blockage of 
polymerisation [l-4]. Clearly for the action of such 
a tool to be interpreted correctly it must exhibit a 
high specificity. 
Some of the events in which microtubules are 
purported to play a role are susceptible to changes in 
cyclic AMPlevels [ 1,2 ,S $1. Indeed, even the assembly 
of microtubules themselves is sensitive to cyclic 
nucleotides [ 1 ,Z ,4,7]. It is important then to appreciate 
the effects of vinblastine on the enzymes of cyclic 
AMP metabolism. This study examines the effect of 
vinblastine on the well-defined glucagon-stimulated 
adenylate cyclase from rat liver plasma membranes 
[8,9]. It dissects out its action on the basal and hor- 
mone-stimulated activities both in the presence and 
absence of the modulator GTP [8,9] which also has a 
central involvement in the polymerisation of micro- 
tubules [l-4]. 
2. Materials and methods 
Plasma membranes were prepared from male 
Sprague-Dawley rats (200-300 g) and adenylate 
cyclase was assayed as detailed in [lo]. Assays were 
performed at a final pH 7.4 with vinblastine present 
and at a plasma membrane concentration of 0.15 mg 
protein/l~ll. Vinblastine did not affect our method of 
assay of the cyclic AMP produced. “‘I-Specific 
glucagon binding to receptors was performed as in 
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[ 1 I]. Protein estimation was by a modified micro- 
biuret method [ 121. 
Plasma membranes (3.25 mg~ml) were incubated 
with a range of rabbit antitubulin antibody (5-50 gg/ml) 
for 30 min at 4°C before aliquots were taken for assay. 
Glucagon was a kind gift from Dr W. W. Bromer of 
Eli Lilly Co., Indiana. Affinity purified rabbit anti- 
chick brain tubulin antibody was a kind gift from 
Dr Daniel Louvard, EMBL, Heidelberg. Vinblastine 
sulphate, creatine kinase, theophylline and creatine 
phosphate were from Sigma. Cyclic AMP, ATP, GTP- 
Na-salt and triethanolamine-HCl were from Boehringer. 
Radiochelnicals were from the Radiochemical Centre, 
Amersham. All other chemicals were of AR quality 
from BDH Chemicals. 
3. Results 
Basal adenylate cyclase activity was apparently 
unaffected by the addition of vinblastine sulphate up 
to 100 FM (fig.1). This contrasts with the situation 
when GTPwas used to stimulate the enzyme, in which 
case a complex result was obtained indicating both 
inhibition and activation phenomena depending upon 
the concentration of vinblastine present. 
When glucagon was added to the assay then 
vinblastine had a marked inhibitory effect. This 
inhibition could apparently be dissected into two 
components each of which caused 20-25s inhibition 
of the total activity but occurred at very different 
concentrations (fig.2). However, when GTP was 
added to the glucagon-stimulated assays then little if 
any in~bition was observed over the entire range of 
drug concentrations tested (fig.2). 
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Fig.1. The effect of vinblastine on the basal and GTP- 
stimulated adenylate cyclase activity of liver plasma mem- 
branes. Adenylate cyclase activity of liver plasma membranes 
in the absence (0) and presence (A) of 100 PM GTP. Errors 
are given as +-SD, n = 6 using 3 different membrane prepara- 
tions. Adenylate cyclase activity was assessed from linear 
timecourses of cyclic AMP production over 10 min at 30°C. 
The assay media was at a final pH 7.4 containing final cont. 
25 mM triethanolamme-HCl, 1 mM EDTA, 1 mM theo- 
phylline, 5 mM MgSO,, 7.4 mg/ml creatine phosphate, 
1 mg/ml creatine phosphate and 1.5 mM ATP. Cyclic AMP 
produced during the assay was monitored as detailed in [lo]. 
Basal activity of adenylate cyclase was 22 I.tunits/mg protein, 
and in the presence of 100 PM GTP was 60 punits/mg protein. 
(One unit is defined as 1 Mmol substrate transformed/mm.) 
When the ‘*‘I-specific glucagon binding was 
followed we observed a loss of -25% of the binding 
at the higher vinblastine concentrations (fig.2). This 
phenomenon occurred at similar vinblastine concen- 
trations to the second phase of inhibition of the 
glucagon-stimulated activity (fig.2). 
These changes in activity were found to be 
effectively instantaneous (<l min) as time courses 
for the assays were linear over a 10 min period and 
not reversed by a simple washing procedure. 
Arrhenius plots of glucagon-stimulated adenylate 
cyclase activity were carried out in the presence and 
absence of 40 PM vinblastine sulphate using 3 different 
membrane preparations (errors are ZSD). In the 
absence of vinblastine a break point at 27.5 f 0.7”C 
was obtained with activation energies of 36 f 5 and 
76 + 10 kJ . mol-’ above and below the break point, 
respectively. In the presence of vinblastine a break 
point at 27.5 + 2.3”C was obtained with activation 
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Fig.2. The effect of vinblastine on “‘I-specific glucagon 
binding to plasma membranes and on the glucagon-stimulated 
adenylate cyclase activity. ‘iS1-Specific glucagon binding (A) 
and glucagon-stimulated adenylate cyclase activity in the 
absence (=) and presence (0) of 100 PM GTP. Errors are given 
as *SD, n = 6 using 3 different plasma membrane preparations. 
Adenylate cyclase was assayed as in fig.1. The specific 
activity of adenylate cyclase at 30°C in the presence of 
10e6 M glucagon was 660 punits/mg and in the presence of 
glucagon plus 100 /.IM GTP was 1.22 munits/mg. Specific 
binding of ‘251-labelled glucagon was carried out in a buffer 
of final pH 7.4 containing 15 mM triethanolamine-HCl, 
1 mM EDTA, 1 mM theophylline, 5 mM MgSO, and 2.5% 
bovine serum albumin with 1 0e9 M ‘251-labelled glucagon 
[ 111 for 10 min at 30” C. The specific component was 
assessed by adding 10 + M unlabelled glucagon (see [ 111). 
Specific binding of 1251-labelled glucagon was 2.0 pmol/mg 
protein. 
energies of 28 f 4 and 55 + 7 kJ . mol-’ above and 
below the break, respectively. 
Treatment of membranes with an affinity purified 
rabbit anti-chick brain tubulin antibody had no effect 
on basal or any of the ligand-stimulated activities. 
4. Discussion 
Vinblastine has profoundly different effects on the 
various ligand-stimulated activities of liver plasma 
membrane adenylate cyclase. The basal activity of the 
enzyme was apparently unaffected at all concentra- 
tions of vinblastine tested implying the insensitivity 
of the catalytic unit of the enzyme to this agent. This 
was not true for the GTP-stimulated activity which 
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exhibited marked changes in activity in response to 
vinblastine (fig.1). There appeared to be 2 or 3 com- 
ponent effects of vinblastine on the GTP-stimulated 
activity of the enzyme. These were an inhibitory 
phenomenon occurring at low vinblastine concentra- 
tions (0 .O 1-O .5 PM) followed by a phase of activa- 
tion at -1 PM vinblastine which sufficed to relieve 
this inhibition. Increases in vinblastine to >2 I.IM led 
to a further phase of inhibition of activity which 
appeared to plateau out at -50% inhibition. This 
GTP-stimulated activity is believed to involve a 
regulatory protein associated with the catalytic unit 
[8,13 ,I 41. It is presumably at this regulatory site that 
vinblastine acts to cause the marked changes in 
activity noted. That these phenomena are only 
observed with the GTP-stimulated state (in the absence 
of hormone) suggests that they are due to vinblastine 
affecting either the guanine nucleotide regulatory 
unit associated with the catalytic unit of adenylate 
cyclase or it may also perturb the mechanism by 
which this regulatory unit activates the catalytic 
unit, or the catalytic unit activated in such a fashion 
by GTP may become sensitive to vinblastine action. 
This is the only stimulated state of the enzyme that 
exhibits an apparent activation by vinblastine (seen as a 
relief of an inhibition) emphasising the difference of 
this state from other stimulated states of the enzyme. 
The low concentrations of vinblastine necessary to 
elicit the activation and inhibitory effect might suggest 
that there are specific sites on this GTP binding pro- 
tein that bear analogy with tubulin [l-4]. As GTP 
attains -0.6 mM in the cell [ 151 it is likely that this 
state would be physiologically relevant. 
The inhibition by vinblastine of the glucagon- 
stimulated state could seemingly be dissected into two 
components. The loss of activity at the higher vin- 
blastine concentrations being due to an apparent loss 
of receptors as indicated by a proportional decrease 
in 1251-labelled glucagon specific binding. This would 
be predicted by the mobile receptor model which is 
believed to apply in this instance [I 1,161, where one 
occupied receptor can activate but a single catalytic 
unit and there is no large excess of receptors over 
catalytic units [11,16]. 
The inhibition at the lower concentrations was 
presumably due to a direct action of vinblastine on 
the coupled transmembrane complex of receptor and 
catalytic unit that would be formed in the presence 
of glucagon [ 11 ,161. Such a state appears to be depen- 
dent on acidic phospholipids [ 171 and is peculiarly 
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sensitive to inhibition by positively charged anaes- 
thetics [ 181 and lysolecithins [ 19 1. It is not unlikely 
that a compound that can interact strongly with mem- 
branes and acidic species [ 1,3,20] by virtue of its 
cationic nature should effect such an inhibition. It is 
then very interesting that the vinblastine inhibited 
states of glucagon-stimulated adenylate cyclase should 
be abolished by the addition of GTP to the assays. 
In the presence of glucagon, GTP binds to a further 
regulatory component which becomes involved in the 
coupling process between the receptor and catalytic 
unit [8,14]. This leads to a fundamental change in 
mechanism, where instead of a transmembrane com- 
plex of receptor and catalytic unit being formed 
upon hormone addition [ 111, a free, activated catalytic 
unit is produced after interaction with the receptor 
and regulatory coupling component [ 16,2 I]. The free- 
activated form of the catalytic unit produced by 
addition of GTP and glucagon is in a very different 
state from the much less active catalytic unit formed 
in the presence of GTP alone [ 16,2 l] and thus would 
not be expected to respond similarly to vinblastine. 
A further consequence of this change in mechanism is 
that in the presence of GTP an occupied receptor can 
activate more than one catalytic unit: probably about 
4 [ 161. If, as seems likely, the inhibition of the 
glucagon-stimulated activity at the higher vinblastine 
concentrations was due to the inhibition of glucagon 
binding and thus the loss of occupied receptors, it is 
not perhaps too surprising that in the presence of 
GTP the inhibition of the glucagon-stimulated rate 
was reversed. Thus the GTP + glucagon stimulated 
activity is relatively insensitive to receptor losses and 
certainly of the amount experienced in this instance 
(see [16]). 
In the presence of GTP and glucagon then no com- 
plex between the receptor and catalytic unit will 
occur as an accumulating active species. Vinblastine 
would not then be expected to cause an inhibition at 
the lower concentrations if such an inhibition was 
indeed due to a peculiar sensitivity of the transmem- 
brane complex to vinblastine. This change in sensitiv- 
ity may be due to an altered conformational state of 
the enzyme as suggested [16,21]. Alternatively the 
change in the disposition of the catalytic unit within 
the bilayer when it is not physically associated with 
the receptor [22] may lead to the loss of any pertur- 
bation vinblastine might achieve between the head- 
groups of acidic phospholipids and the catalytic unit. 
Vinblastine sulphate has been shown to affect 
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Na+/K+ ATPase and other membrane transport 
systems [23,24] and it has been suggested that this 
may be due to a general membrane expansion effect 
[20]. This, however, is unlikely to account for the 
inhibitory or activation phenomena observed in this 
study as the concentrations of vinblastine necessary 
to achieve membrane expansion [20] are some orders 
of magnitude higher than those tested here. Arrhenius 
plots of glucagon-stimulated adenylate cyclase activity 
demonstrated a well-defined break at -28°C due to a 
lipid-phase separation occurring in the membrane [lo]. 
This was unaffected by the presence of vinblastine 
which mitigates against any gross perturbation of the 
lipid phase mediating these phenomena. 
It has been suggested that the organisation of mem- 
brane proteins may be regulated by microtubule 
assemblies that interact with the plasma membrane 
and that these would be disrupted by vinblastine 
[25,26]. If tubulin was associated with any of the 
protein species of our system and this was responsible 
for the effects of vinblastine then crosslinking of such 
components using anti-tubulin antibody might well 
be expected to alter the response to those ligands 
where free lateral diffusion of components is a pre- 
requisite for activation [ 11 ,16,2 11. However, in our 
hands anti-tubulin antibody had no effect on any 
ligand-stimulated activity. 
The simplest interpretation of our results is that 
vinblastine can act directly on the various compo- 
nents of the adenylate cyclase system. These sites can 
be identified by the susceptibility of different ligand- 
stimulated activities to inhibition. We propose that 
there are two sites affecting the action of glucagon on 
the adenylate cyclase system. These are a site of high 
affinity which perturbs the coupling between the 
receptor and catalytic unit of adenylate cyclase, 
occupancy of which causes inhibition. A further site 
of lower affinity inhibits binding of glucagon to its 
receptor, which again causes loss of hormone-stimulated 
activity. There then appears to be 2 or 3 other sites 
that are apparent from observations of the GTP- 
stimulated state (in the absence of hormone) and are 
presumably associated with the GTP-regulatory unit 
attached to the catalytic unit. Occupancy by vinblastine 
of these sites can lead to either inhibition or activa- 
tion phenomena. That such changes occur in the 
activity of adenylate cyclase to vinblastine, and at 
such low concentrations, requires that care be taken 
when attributing the mode of action of vinblastine on 
cellular systems. This is especially true when many 
phenomena are affected by cyclic nucleotide levels 
and the vinblastine concentrations used to disrupt 
microtubules are in the range affecting adenylate 
cyclase activity. Our results may have significance in 
the use of vinblastine for treating Hodgkin’s disease 
and certain cancers [27]. For at the doses used in 
clinical practice it is not unlikely that blood levels 
may attain 0.05-0.1 PM vinblastine [27], which 
would suffice to allow the occurrence of some of the 
effects discussed here. 
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